Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
681-700 of 1,694 trials

Heart Failure: Stopping Beta-Blockers

We are studying whether discontinuing beta-blockers is as safe for patients with improved heart function as continuing the medication. This trial aims to understand the effects on heart failure relapse and overall heart health.

Heart Failure>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Refractory Focal Onset Epilepsy: BHV-7000 Study

We are testing a new medication, BHV-7000, to see if it can help reduce seizures in adults with refractory focal onset epilepsy. The study compares its effects to a placebo to evaluate safety and effectiveness.

Focal Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

BHV-7000 for Idiopathic Generalized Epilepsy

We are studying a new treatment for people with idiopathic generalized epilepsy who have generalized tonic-clonic seizures. The trial will compare its effects to a placebo to see if it helps reduce seizure frequency and is safe to use.

Idiopathic Generalized Epilepsy6-12 monthsEfficacy phase (II)Confirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Refractory Focal Onset Epilepsy: BHV-7000 Safety Study

We are evaluating the safety and tolerability of BHV-7000 in adults with refractory focal onset epilepsy. This study aims to ensure the treatment is safe for those who have not found relief with other options.

Focal Epilepsy1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Non-Small Cell Lung Cancer: Neoadjuvant and Adjuvant Treatment Study

We are studying a new treatment approach for patients with resectable non-small cell lung cancer to see if it improves tumor response and safety before and after surgery.

Non-small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Heart Failure: Finerenone and SGLT2 Inhibitor Study

We are investigating whether a combination of finerenone and an SGLT2 inhibitor can improve health outcomes for hospitalized heart failure patients. This study aims to see if this approach leads to better symptom relief and fewer hospital visits.

Heart Failure1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Heart Failure: Finerenone Study

We are testing the medication finerenone for patients with heart failure who cannot tolerate standard treatments. The study aims to see if it is safe and effective for these individuals.

Heart Failure>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Myeloid Malignancies: BGB-11417 Study

We are testing a new drug, BGB-11417, in combination with azacitidine for patients with myeloid malignancies. The goal is to find the safest dose and see how well it works against the disease.

Myeloid MalignanciesSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Atrial Fibrillation: Rivaroxaban Monotherapy Study

We are exploring the safety of rivaroxaban in patients with atrial fibrillation who have had a heart procedure. This study aims to see if this treatment is a viable option for these patients.

Coronary Artery DiseasePercutaneous Coronary InterventionAtrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Prednisolone Transfer in Breast Milk: A Study for Breastfeeding Mothers

We are investigating how prednisolone, used for inflammation, transfers into breast milk and affects breastfeeding infants. This study aims to measure medication levels in both mothers and their babies to ensure safety.

Rheumatoid ArthritisSystemic Lupus ErythematosusMyositis≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicinePediatrics

Advanced Lung Cancer: Adagrasib and Pembrolizumab Study

We are testing a new treatment combining adagrasib with pembrolizumab for patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The goal is to see if this combination works better than pembrolizumab alone.

Advanced Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Medical Cannabis Aerosol for Diabetic Peripheral Neuropathic Pain

We are studying whether a medical cannabis aerosol can help reduce pain for people with diabetic peripheral neuropathic pain. Participants will compare different doses of THC to a placebo to assess pain relief and quality of life.

Diabetic Peripheral Neuropathic Pain3-6 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNeurology

Eosinophilic Esophagitis: BP1.7881 Treatment Study

We are testing a new medication, BP1.7881, for adults with eosinophilic esophagitis to see if it can improve their condition. The study will also look at how safe and well-tolerated the treatment is.

Eosinophilic Esophagitis3-6 monthsEfficacy phase (II)≤5 visitsPartially RemoteAllergologyGastroenterology

High-Grade Glioma in Children: Larotrectinib Treatment

We are studying the effects of larotrectinib on young children with newly diagnosed high-grade glioma that has an NTRK fusion. The trial will help us understand how well it works and its safety when used alone or with chemotherapy.

High Grade Glioma (HGG)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Acute Vaginal Infection: BGY-1601-VT Tablet

We are studying a new vaginal tablet for women with acute vaginal infections to see if it works better than a placebo. The trial will help us understand its safety and effectiveness for conditions like Bacterial Vaginosis and Vulvovaginal Candidiasis.

Gynecological Conditions1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesGynecology and ObstetricsInfectious Diseases

HER2-Positive Breast Cancer: Zanidatamab vs. Trastuzumab

We are studying whether zanidatamab combined with chemotherapy is more effective and safer than trastuzumab with chemotherapy for patients with metastatic HER2-positive breast cancer who have not responded to previous treatments.

Metastatic HER2-positive Breast Cancer3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Hypertrophic Cardiomyopathy: Aficamten Study

We are evaluating the long-term safety and tolerability of aficamten in adults with hypertrophic cardiomyopathy. The study also looks at its effects on heart function in patients with obstructive HCM.

Hypertrophic Cardiomyopathy1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Autoimmune Disease: Ianalumab Delivery Methods

We are comparing two ways to deliver ianalumab to adults with autoimmune diseases. This study will help us understand how well the medication works and its safety when given in different forms.

Sjögren's DiseaseRheumatoid ArthritisSystemic Lupus Erythematosus6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineRheumatology

Pancreatic Cancer: Antiplatelet Therapy Study

We are investigating if adding an antiplatelet medication to standard care can help prevent blood clots in patients with pancreatic cancer. We also want to see if it may improve survival rates.

Pancreatic Ductal Cancer6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyOncology

Vedolizumab for Children with Moderate to Severe Crohn's Disease

We are studying how well different doses of vedolizumab help children and teenagers with Crohn's disease maintain their health. The goal is to see if it can keep symptoms under control and improve their overall well-being.

Crohn's Disease1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics